Targets › CEBPA
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Apr 2027.
Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes. (UniProt, P49715)
Open in Phaseline: the race on CEBPA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National University Hospital, Singapore | MTL-CEBPA RNA oligonucleotide targeting CEBPA (C/EBP-alpha) | CEBPA | Phase 1 | Advanced Hepatocellular Carcinoma | Apr 2027 |
| Pacylex Pharmaceuticals | zelenirstat (PCLX-001) C/EBP alpha activator | CEBPA | Phase 1 | Relapsed Adult AML | – |
Advanced Hepatocellular Carcinoma (1) Relapsed Adult AML (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.